Globeflex Capital L P Has $560,000 Holdings in ANI Pharmaceuticals Inc (ANIP)

Globeflex Capital L P trimmed its stake in ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 19.5% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,900 shares of the specialty pharmaceutical company’s stock after selling 2,400 shares during the quarter. Globeflex Capital L P’s holdings in ANI Pharmaceuticals were worth $560,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the company. BlackRock Inc. boosted its stake in shares of ANI Pharmaceuticals by 7.3% during the 2nd quarter. BlackRock Inc. now owns 1,391,174 shares of the specialty pharmaceutical company’s stock worth $92,931,000 after acquiring an additional 94,786 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of ANI Pharmaceuticals by 2.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 479,325 shares of the specialty pharmaceutical company’s stock worth $32,019,000 after acquiring an additional 11,081 shares during the period. Nomura Holdings Inc. boosted its stake in shares of ANI Pharmaceuticals by 10.0% during the 2nd quarter. Nomura Holdings Inc. now owns 310,115 shares of the specialty pharmaceutical company’s stock worth $20,716,000 after acquiring an additional 28,134 shares during the period. First Manhattan Co. boosted its stake in shares of ANI Pharmaceuticals by 48.0% during the 3rd quarter. First Manhattan Co. now owns 215,695 shares of the specialty pharmaceutical company’s stock worth $12,195,000 after acquiring an additional 70,000 shares during the period. Finally, Northern Trust Corp boosted its stake in shares of ANI Pharmaceuticals by 4.2% during the 2nd quarter. Northern Trust Corp now owns 116,806 shares of the specialty pharmaceutical company’s stock worth $7,803,000 after acquiring an additional 4,710 shares during the period. Institutional investors own 62.29% of the company’s stock.

Several brokerages have recently commented on ANIP. ValuEngine downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, July 28th. BidaskClub downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 1st. Cantor Fitzgerald set a $74.00 target price on ANI Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, August 7th. Finally, Canaccord Genuity set a $75.00 price target on ANI Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 16th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. ANI Pharmaceuticals presently has an average rating of “Buy” and an average target price of $71.00.

ANIP opened at $55.12 on Friday. The firm has a market capitalization of $653.50 million, a P/E ratio of 15.27 and a beta of 2.64. ANI Pharmaceuticals Inc has a 1 year low of $48.40 and a 1 year high of $74.70. The company has a quick ratio of 2.49, a current ratio of 3.34 and a debt-to-equity ratio of 1.04.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $1.29 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.17 by $0.12. The business had revenue of $50.70 million during the quarter, compared to the consensus estimate of $50.97 million. ANI Pharmaceuticals had a return on equity of 28.39% and a net margin of 0.23%. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.11 EPS. On average, research analysts expect that ANI Pharmaceuticals Inc will post 4.54 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Globeflex Capital L P Has $560,000 Holdings in ANI Pharmaceuticals Inc (ANIP)” was first posted by WKRB News and is owned by of WKRB News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.wkrb13.com/2018/11/23/globeflex-capital-l-p-has-560000-holdings-in-ani-pharmaceuticals-inc-anip.html.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis.

Read More: Fundamental Analysis – How It Helps Investors

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals Inc (NASDAQ:ANIP).

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply